Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

December 19, 2017

Primary Completion Date

July 5, 2019

Study Completion Date

April 13, 2020

Conditions
Biliary Tract Cancer
Interventions
DRUG

Varlitinib

oral tablets, twice daily

DRUG

Capecitabine

oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles

Trial Locations (2)

Unknown

No.81 Hospital of The Chinese People's Liberation Army, Nanjing

There is 22 sites located in other cities of China, including Nanjing, Nanjing

Sponsors
All Listed Sponsors
lead

ASLAN Pharmaceuticals

OTHER